Prudential plc stock ticks up after Malaysia stake deal closes as buyback rolls on
30 January 2026
1 min read

Prudential plc stock ticks up after Malaysia stake deal closes as buyback rolls on

London, January 30, 2026, 09:10 GMT — Regular session

  • Prudential shares climbed roughly 0.4% in early London trading following the insurer’s confirmation that it completed its Malaysia stake increase.
  • The company announced an additional on-market share buyback aimed at cancellation.

Prudential shares ticked up on Friday following the insurer’s announcement that it has finalized a deal, raising its effective stake in Prudential Assurance Malaysia Berhad’s parent company to 70%.

The stock gained 0.4% to 1,201 pence, roughly 12.01 pounds, in early trading. 1

This update is significant as Malaysia stands as one of Prudential’s crucial markets in Southeast Asia. The shift hands the company greater control over earnings and distribution within a business it already operates locally.

Investors remain watchful on capital deployment. Prudential has been funneling cash into buybacks, and the market is on edge over how fast those programmes eat up capacity that might otherwise fund deals or bolster buffers.

Prudential announced it has fulfilled all contractual conditions to acquire an extra 19% stake in Sri Han Suria Sdn. Bhd., the holding firm behind Prudential Assurance Malaysia Berhad, boosting its total ownership to 70%. The company did not disclose financial details in the statement released Friday. 1

Separately, Prudential repurchased 300,151 shares on Jan. 29 at an average price of 12.0514 pounds each, with plans to cancel them. The buyback was executed via JP Morgan Securities as part of the company’s wider share repurchase programme. 2

The shares are hovering close to the upper end of their 12-month range, which Investing.com lists as 653.4 to 1,219.5 pence. 3

Prudential’s main focus is life and health insurance across Asia and Africa, vying for savings and protection alongside regional players like AIA. This exposure leaves its stock more vulnerable to local regulatory changes and currency fluctuations than many other UK-listed rivals.

Still, the upside hinges on flawless execution. Any hiccup in Malaysia—be it governance issues, minority shareholder tensions, or weak operating results—could erode the gains from a larger stake. That risk grows if investors begin pressing more on capital constraints and strategic priorities.

Prudential is set to release its full-year results on March 19 (or late March 18 UK time). Investors will be watching closely for updates on the company’s capital position, the speed of its buyback program, and any insights from Malaysia regarding growth and margins. 4

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
3i Group share price dips after Action sales update — and a £1bn stake deal lands
Previous Story

3i Group share price dips after Action sales update — and a £1bn stake deal lands

National Grid share price edges up in London trade as rate outlook and UK grid approvals stay in focus
Next Story

National Grid share price edges up in London trade as rate outlook and UK grid approvals stay in focus

Go toTop